Nicolas Lambert Majdouline El Moussaoui Caroline Ritacco Martin Moïse Astrid Paulus Philippe Delvenne Frédéric Baron Bernard Sadzot Pierre Maquet
10.3389/fimmu.2022.889148
Front Immunol
2022 May 3;13:889148.
jc virus (jcv) pd1 and pdl1 pml - progressive multifocal leucoencephalopathy atezolizumab immune checkpoint inhibitors (ici) immunotherapy lung adecarcinoma non small cell lung cancer (nsclc)
CC BY
https://pubmed.ncbi.nlm.nih.gov/35592313/
Carcinoma, Non-Small-Cell Lung / complications Carcinoma, Non-Small-Cell Lung / drug therapy JC Virus Leukoencephalopathy, Progressive Multifocal / diagnosis Leukoencephalopathy, Progressive Multifocal / drug therapy Leukoencephalopathy, Progressive Multifocal / etiology Lung Neoplasms / complications Lung Neoplasms / drug therapy Opportunistic Infections / drug therapy
Carcinoma, Non-Small-Cell Lung / complications Carcinoma, Non-Small-Cell Lung / drug therapy JC Virus Leukoencephalopathy, Progressive Multifocal / diagnosis Leukoencephalopathy, Progressive Multifocal / drug therapy Leukoencephalopathy, Progressive Multifocal / etiology Lung Neoplasms / complications Lung Neoplasms / drug therapy Opportunistic Infections / drug therapy Case Reports Research Support, Non-U.S. Gov't Aged Antibodies, Monoclonal, Humanized Humans Immune Checkpoint Inhibitors / therapeutic use Male Antibodies, Monoclonal, Humanized Immune Checkpoint Inhibitors atezolizumab
PMC9110816
35592313
Killing Two Birds With One Stone: Effective Control of Both Non-Small Cell Lung Cancer and Progressive Multifocal Leukoencephalopathy With Atezolizumab, A Case Report
2022